- Home
- GLTO vs MBRX Comparison
GLTO vs MBRX Comparison
Compare GLTO & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- MBRX
- Stock Information
- Founded
- GLTO 2011
- MBRX 2015
- Country
- GLTO Denmark
- MBRX United States
- Employees
- GLTO N/A
- MBRX N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- GLTO Health Care
- MBRX Health Care
- Exchange
- GLTO Nasdaq
- MBRX Nasdaq
- Market Cap
- GLTO 7.5M
- MBRX 7.0M
- IPO Year
- GLTO 2020
- MBRX 2016
- Fundamental
- Price
- GLTO $4.70
- MBRX $1.67
- Analyst Decision
- GLTO Buy
- MBRX Strong Buy
- Analyst Count
- GLTO 1
- MBRX 3
- Target Price
- GLTO $10.00
- MBRX $31.00
- AVG Volume (30 Days)
- GLTO 20.6K
- MBRX 49.2K
- Earning Date
- GLTO 11-01-2024
- MBRX 11-08-2024
- Dividend Yield
- GLTO N/A
- MBRX N/A
- EPS Growth
- GLTO N/A
- MBRX N/A
- EPS
- GLTO N/A
- MBRX N/A
- Revenue
- GLTO N/A
- MBRX N/A
- Revenue This Year
- GLTO N/A
- MBRX N/A
- Revenue Next Year
- GLTO N/A
- MBRX N/A
- P/E Ratio
- GLTO N/A
- MBRX N/A
- Revenue Growth
- GLTO N/A
- MBRX N/A
- 52 Week Low
- GLTO $4.40
- MBRX $0.40
- 52 Week High
- GLTO $23.50
- MBRX $6.24
- Technical
- Relative Strength Index (RSI)
- GLTO 26.70
- MBRX 30.60
- Support Level
- GLTO $4.40
- MBRX $1.81
- Resistance Level
- GLTO $5.42
- MBRX $3.10
- Average True Range (ATR)
- GLTO 0.37
- MBRX 0.25
- MACD
- GLTO -0.01
- MBRX -0.10
- Stochastic Oscillator
- GLTO 16.81
- MBRX 0.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.